Clazakizumab

N/A

Report date: 2026/04/10 20:01:49

Base Information

Drug NameClazakizumab
Drug Alias NameBMS-945429BMS-645429ALD518-003ALD-518CSL300 +[6
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterleukin-6 inhibitors
TargetsInterleukin-6
Therapy Area/IndicationsRejection of organ transplantationCoronavirus Disease 2019 (COVID-19)Fatigue +[19
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[42
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAlder Biopharmaceuticals
China Registration ClassN/A

Develop Information

Active IndicationsCoronavirus Disease 2019 (COVID-19)InflammationFrailty +[9
Inactive IndicationsRejection of organ transplantationFatigueCachexia +[10

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBank